| CENTRAL-LABORATORIES |
CENTRAL-LABORATORIES |
90%
|
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and … |
| CLINICAL-TRIAL-SITES |
CLINICAL-TRIAL-SITES |
90%
|
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and … |
| CONTRACT-MANUFACTURING-ORGANIZATIONS |
CONTRACT-MANUFACTURING-ORGANIZATIONS |
90%
|
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and … |
| CONTRACT-RESEARCH-ORGANIZATIONS |
CONTRACT-RESEARCH-ORGANIZATIONS |
90%
|
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and … |
| SWISS-CANCER-INSTITUTE |
SWISS-CANCER-INSTITUTE |
80%
|
In October 2024, in collaboration with the Swiss Cancer Institute, formerly the Swiss Cancer Group for Clinical Cancer Research (SAKK), we initiated and dosed our first patient in a Phase 2 study |
| GILD |
Gilead Sciences, Inc. |
72%
|
n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may assert that a claim that includes items o… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false … |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ORAN… |
| ORANY |
ORANY |
72%
|
ess and monitor the product’s safety and effectiveness after commercialization. FDA may also condition approval of a drug product on the development and approval of a REMS. A REMS could include medic… |
| REPL |
Replimune Group, Inc. |
72%
|
n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may assert that a claim that includes items o… |
| REPL |
Replimune Group, Inc. |
72%
|
Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: Reciprocal relationship from REPL g… |
